Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 978 participants.

Also called NCT07002476

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 978 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07002476
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07002476. Randomized; single masking; primary purpose treatment. Start 2025-06-19 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
Acronym
EAST-LDL
Condition
Stroke
Intervention (Drug)
guideline-recommended SoC
Intervention (Drug)
Recaticimab (intensive)
Lead sponsor
Shanghai East Hospital (class: other)

Record details

Record id
cardio:ct-nct07002476
Content hash
392b3fb61e8fe197de2a426f39e3e987e89ec2fb59b54bcad2ea77b4a8b83516